Zobrazeno 1 - 10
of 880
pro vyhledávání: '"tirzepatide"'
Publikováno v:
Pragmatic and Observational Research, Vol Volume 15, Pp 139-149 (2024)
Dimitrios Patoulias,1,2 Theocharis Koufakis,2 Ieva Ruža,3 Mohamed El-Tanani,4 Manfredi Rizzo5 1Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, General Hospital “hippokration”, Aristotle University of The
Externí odkaz:
https://doaj.org/article/85e35648610c406ab24b0cea0b5ba4fe
Autor:
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, Ada Pesapane, Manuela Giovanna Basilicata, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Maria Teresa Vietri, Annalisa Capuano, Giuseppe Paolisso, Michelangela Barbieri
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients with type 2 diabetes. It can lead
Externí odkaz:
https://doaj.org/article/4ca156c215ba43d686dcdf0858b6834f
Publikováno v:
JAAD Case Reports, Vol 50, Iss , Pp 123-125 (2024)
Externí odkaz:
https://doaj.org/article/816fe69c32164e9d8a41beb309efc1c7
Publikováno v:
European Journal of Case Reports in Internal Medicine (2024)
Tirzepatide, a modified protein containing 39 amino acids, acts as a dual agonist at the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, showing great promise in weight-loss treatment. While rare, there have been r
Externí odkaz:
https://doaj.org/article/47c64642ee5247c3a64da21f80329b1a
Autor:
Matthew Anson, Alex E. Henney, Nicholas Broadwell, Sizheng S. Zhao, Gema H. Ibarburu, Gregory Y.H. Lip, John P.H. Wilding, Daniel J. Cuthbertson, Uazman Alam
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102777- (2024)
Summary: Background: Tirzepatide, a novel dual agonist of glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), has demonstrated greater magnitude of weight loss compared to semaglutide in a phase 3 clinical trial. H
Externí odkaz:
https://doaj.org/article/93b14b0a5d844a77bc3a8c1845bb3ae3
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Tirzepatide, a novel GLP-1/GIP dual receptor agonist, shows significant advantages in glycemic management and weight control. By summarizing the results of the SURMOUNT and SURPASS clinical trials, we evaluate the efficacy and safety of tirzepatide i
Externí odkaz:
https://doaj.org/article/8625d115343a43549a4499a14d083508
Autor:
Michal Rabenda, Adam Słomczyński, Piotr Zatyka, Agata Pawłowska, Dominika Opala, Dobromiła Osuch, Piotr Janik
Publikováno v:
Quality in Sport, Vol 20 (2024)
Abstract: Obesity is a chronic and insidious disease that represents a significant global. The World Health Organization has announced that almost 60% of European adults are overweight or obese. Complex hormonal and metabolic adaptations in obesit
Externí odkaz:
https://doaj.org/article/515a08010a91439f83337486d54f6de8
Autor:
Arkadiusz Staroń, Patrycja Karkos, Katarzyna Kuśmierczyk, Bartłomiej Gastoł, Karolina Mikołap, Marta Kras, Marta Jurga
Publikováno v:
Quality in Sport, Vol 19 (2024)
In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2. Tirzepati
Externí odkaz:
https://doaj.org/article/f42969db71744c7790a607e7282657c2
Autor:
Qiyuan Keith Liu
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two incretins that bind to their respective receptors and activate the downstream signaling in various tissues and organs. Both GIP and GLP-1 play roles in reg
Externí odkaz:
https://doaj.org/article/ca9126e17fae476d95d58c93f98c3adc
Autor:
Katarzyna Wiśniewska, Julita Gmitrzuk, Zuzanna Malinka, Anna Jachymek, Martyna Opatowska, Joanna Jakubiec, Tomasz Kucharski, Marta Piotrowska
Publikováno v:
Quality in Sport, Vol 15 (2024)
Introduction Obesity results from a complex interplay of environmental, genetic, and behavioral factors, making it challenging to treat. Globally, the prevalence of obesity has tripled over the past fifty years. The WHO reports that 60% of Europea
Externí odkaz:
https://doaj.org/article/1ffeff05747645ccaff041e0da79d5a8